Akeso presents positive HARMONi 2 trial survival data at WCLC
Akeso presented positive overall survival results from its Phase III HARMONi 2 trial comparing ivonescimab to pembrolizumab in non small cell lung cancer patients at the World Conference on Lung Cancer
On September 13, 2026, Akeso, Inc. presented positive overall survival (OS) results from the HARMONi-2 study at the World Conference on Lung Cancer (WCLC). The Phase III, double-blind, multicenter, registrational study aimed to evaluate ivonescimab, a next-generation immuno-oncology therapy, against pembrolizumab as first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC).
The study demonstrated significant benefits of ivonescimab in prolonging OS compared to pembrolizumab, particularly in the PD-L1-high population and squamous NSCLC patients.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
